Relief Therapeutics Holding SA (SWX: RLF) (OTCQB: RLFTF) is getting noticed by investors as its main compound RLF-100 continues to gain traction as a transformative therapeutic option for critical #COVID19. A growing number of cases treated with RLF-100 are leading to rapid recovery from respiratory in patients critically ill from coronavirus and its being picked up by mainstream press. Fox News Houston stated this week that “Patients had a nine-fold chance of survival and recovery from respiratory failure, after being treated with RLF-100.
Of importance to Relief is the Extraordinary General Meeting (EGM) of shareholders on December 17 to vote on several important fronts including an increase of authorized share capital, increase of additional share capital, executive compensation and the election of Tom Plitz as new member of the Board of Directors.
Relief Therapeutics Holding SA (SWX: RLF) (OTCQB: RLFTF) founded by high level Merck executives focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief holds patents issued in the U.S. and multiple other countries covering potential formulations of RLF-100(TM). Relief’s partner; NeuroRx is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca including CEO Dr. Jonathan Javitt who is leading the trial of Aviptadil. Dr. Javitt has an impressive background. He’s the CEO of Neuro-RX, an adjunct professor at Johns Hopkins University and. He has held healthcare leadership roles under four presidents of the United States.Relief is listed on the Swiss Exchange under the symbol RLF and quoted in the U.S. on the OTCQB under the symbol RLFTF
Relief’s lead candidate RLF-100(TM) (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Sami Said’s original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100(TM) for the treatment of COVID-19 and awarded Fast Track designation. RLF-100(TM) is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100(TM) under FDA-approved protocols.
Last week Relief announced more than 175 patients with Critical COVID-19 and Respiratory Failure who also have a severe comorbidity have now been entered into an Expanded Access Protocol (EAP) with RLF-100(TM) in the United States. All patients had severe comorbidities (such as organ transplant, recent heart attack, and cancer) that rendered them ineligible for the ongoing randomized, controlled phase 2b/3 trial being conducted to ascertain safety and efficacy of RLF-100(TM), and all patients were deteriorating despite treatment with approved therapies for COVID-19. Of the 90 patients who have so far reached 28 days of follow-up, 72% survived to day 28.
To Find out the inside Scoop on Relief Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
RLF-100 has been getting picked up by mainstream media and was featured on Fox News 26 in Houston this week. According to the article: “Researchers say a study taking place at Houston Methodist Hospital looks promising to treat the most severe patients. New results show patients had a nine-fold chance of survival and recovery from respiratory failure, after being treated with Aviptadil, also known as RLF-100. Dr. Javitt said that so far, even the most critically ill patients are improving in just a matter of days after treatment. A great aspect of RLF-100 is that peptides can be manufactured synthetically in huge quantities and relatively inexpensively. If the FDA approves this treatment, Dr. Javitt says 30,000 doses could roll out by March, then many more on a regular basis.
Currently, 25 U.S. hospitals have enrolled patients in the EAP, nearly all of which are community hospitals, suggesting that RLF-100(TM) can demonstrate effectiveness in the hands of front-line physicians who deliver the majority of care to patients with Critical COVID-19. Physicians enrolling patients in the EAP have routinely reported that initial patients at their sites have frequently been in the ICU for several weeks without recovery prior to treatment with RLF-100(TM). As patients are treated earlier in the course of their ICU stay, there is an emerging clinical impression that RLF-100(TM) has an even greater impact on recovery.
On December 17 Relief will hold an Extraordinary General Meeting (EGM) of shareholders. Shareholders will vote on several important fronts including an increase of authorized share capital, increase of additional share capital, executive compensation and the election of Tom Plitz as new member of the Board of Directors.
Dr. Javitt stated: “We are reassured that emerging real-world data on the use of RLF-100(TM) in improving survival in patients with Critical COVID-19 are comparable to results seen in the hands of major academic teaching centers. We hope that these findings are viewed as encouraging at a time when many Americans, including the doctors, nurses, and other front-line caregivers who are the heart of our initiative, are celebrating the Thanksgiving holiday at a distance from their loved ones. We look forward to completing enrollment and reporting the results of our pivotal U.S. clinical trial.”
— mattacuss (@mattacussss) November 25, 2020
For more on Relief Therepuetics Subscribe Right Now!
Relief Therapeutics has been trending upwards in recent days on heavy buying coming in from Switzerland. RLFTF is among the most exciting and dynamic stories on the OTCQB that has become the darling of small caps as its wunderdrug Aviptadil continues to demonstrate very positive results in the fight against coronavirus (COVID-19) with no other therapeutic in trials having the success rate of RLF-100. Aviptadil has been granted FDA Fast Track Designation and emergency IND authorization and inhaled delivery of RLF-100™ for the treatment of Critical COVID-19 with respiratory. RLF-100™ is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 210 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100™ under FDA-approved protocols. A growing number of cases treated with RLF-100 are leading to rapid recovery from respiratory in patients critically ill from coronavirus and its being picked up by mainstream press. Fox News Houston stated this week that “Patients had a nine-fold chance of survival and recovery from respiratory failure, after being treated with RLF-100. We will be updating on Relief on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with Relief.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in Relief either long or short and we have not been compensated for this article.